bims-exocan Biomed News
on Exosomes roles in cancer
Issue of 2025–10–12
seven papers selected by
Muhammad Rizwan, COMSATS University



  1. Int J Oncol. 2025 Dec;pii: 101. [Epub ahead of print]67(6):
      Lung cancer (LC) is a lethal malignancy that can pose a serious risk to a patient's health. Tumor metastasis is associated with a shorter survival and poor therapeutic outcomes. Epithelial‑mesenchymal transition, cell proliferation and angiogenesis are the key drivers of metastasis, which accounts for cancer malignancy. Exosomal microRNAs (miRNAs) are miRNAs packed and released in exosomes. Exosomal miRNAs promote the metastasis of LC. As the amount and type of exosomal miRNAs are disrupted in pathological situations, they may serve as markers for the diagnosis and treatment of LC. The present review summarizes the effects and underlying mechanisms of exosomal miRNAs in LC metastasis. It also provides an overview of the potential of exosomal miRNAs as diagnostic indicators and therapeutic targets for LC metastasis, highlighting novel avenues for future tailored therapies.
    Keywords:  exosomal; lung cancer; metastasis; microRNAs
    DOI:  https://doi.org/10.3892/ijo.2025.5807
  2. Future Oncol. 2025 Oct 10. 1-14
       PURPOSE: The present retrospective observational study was designed to explore the expression deregulation of exosomal microRNAs, hsa-miR-144-3p, hsa-miR-4262, and related genes in brain tumor patients.
    METHODS: Exosomes were extracted from 400 brain tumor patients and 400 controls and characterized using DLS, TEM, and ELISA. Quantitative PCR was used to check the expression level of hsa-miR-144-3p, hsa-miR-4262, phosphatidylinositol-3-kinase (PI3K) and AKT kinase (AKT) in study cohort. CMV level in brain tumor patients was checked by quantifying UL83.
    RESULTS: Data analysis showed significant deregulation of hsa-miR-144-3p (p < 0.0001), hsa-miR-4262 (p < 0.0001), PI3K (p < 0.0001), and AKT (p < 0.0001) in brain tumor patients. Conclusions: ROC curve analysis showed that deregulation of hsa-miR-144-3p, hsa-miR-4262, PI3K, and AKT may act as good diagnostic markers for brain tumor patients.
    Keywords:  Extracellular vesicles; HCMV; brain tumor; exosomal microRNA; quantitative PCR
    DOI:  https://doi.org/10.1080/14796694.2025.2569097
  3. Nat Rev Clin Oncol. 2025 Oct 08.
      Extracellular vesicles (EVs) encompass a multitude of lipid bilayer-delimited particles, of which exosomes are the most widely studied. Bidirectional cell-cell communications via EVs have a pivotal role in the physiology of multicellular organisms. EVs carry biological cargoes (including proteins, RNA, DNA, lipids and metabolites) capable of mediating a range of pleiotropic cellular functions. Over the past decade, EVs released by cancer cells (onco-EVs) have been shown to promote cancer progression including tumour outgrowth and metastatic dissemination. Furthermore, the innate ability of EVs to protect vulnerable molecular cargoes (such as RNA, DNA or proteins) from enzymatic degradation, their presence in most biofluids and the ability to transverse biological barriers to reach distant organs make them ideal targeted drug delivery systems, including in patients with cancer. Many of these properties also support investigations of EVs as biomarkers with potential roles in both diagnosis and treatment monitoring. In this Review, we describe advances in the development of EVs as cancer therapeutics or biomarkers, including cancer vaccines, targeted drug delivery systems and immunotherapies, as well as potential roles in early cancer detection, diagnosis and clinical management. We also describe the potential of emerging technologies to support further discoveries as well as the clinical translation of EVs into diagnostic and therapeutic clinical tools. We highlight the potential of single-EV and onco-EV detection and discuss how advances in multi-omic and artificial intelligence-enabled integration are providing new biological insights and driving clinical translation.
    DOI:  https://doi.org/10.1038/s41571-025-01074-2
  4. Cell Death Discov. 2025 Oct 06. 11(1): 434
      Current advances in oncology have recognized two distinct cell subpopulations in tumors that include (1) a rare subpopulation, cancer stem cells (CSCs), which is considered to be the "seed" of the tumor, with therapy-resistant properties and as key drivers of tumor aggressiveness, and (2) the remaining bulk one, non-CSCs, all differentiated from the CSCs. Within the tumor microenvironment (TME), exosomes secreted by either CSCs or non-CSCs, containing multiple biomolecular cargos, mediate communication between both of the tumor cell subpopulations and play a vital role in promoting tumor progression. Specifically, a class of biomolecular cargo, non-coding RNAs (ncRNAs) that do not code for proteins during translation, has recently been highlighted to be a key participant in oncobiological processes. To comprehensively illuminate the mechanism of exosomal ncRNAs in mediating bidirectional communication between CSCs and differentiated tumor cells within the TME, we systematically analyzed the state-of-the-art literature from PubMed on this topic. It is revealed that: (1) Non-CSC exosomal ncRNAs enhance CSC stemness via upregulating stemness marker expression and activating stemness-reinforcing signaling pathways; (2) CSC-derived exosomal ncRNAs reciprocally mediate tumor progression by enhancing stemness, metastasis, angiogenesis, chemoresistance, and immune suppression of non-CSCs; (3) These tumor-derived exosomal ncRNAs possess the potentials as liquid biopsy biomarkers for early metastasis detection, and treatment targets or drug delivery systems for precision cancer therapy. It is therefore concluded that exosomal ncRNAs serve as critical communication bridges within TME, creating a self-reinforcing tumor-promoting loop, and therapeutically targeting exosomal ncRNAs could disrupt the crosstalk between CSCs and non-CSCs to delay the tumor progression. These findings provide a framework for developing combinatorial strategies against therapy-resistant malignancies.
    DOI:  https://doi.org/10.1038/s41420-025-02726-z
  5. Ther Deliv. 2025 Oct 05. 1-19
      Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cancer treatment, but it has severe side effects. Extracellular vesicles (EVs), nanovesicles released by CAR T cells, known as CAR T-cell-derived EVs (CAR-EVs), are a potential alternative owing to their role in intercellular communication. This review comprehensively explores the clinical potential of CAR-EVs for cancer therapy, starting with their biogenesis and cargo, which include unique therapeutic molecules. It reviews the mechanisms underlying CAR-EV-mediated anticancer effects and presents preclinical evidence demonstrating efficacy across various cancers, including hematological malignancies and solid tumors. The review further discusses preclinical data and advantages over existing CAR T-cell therapies, emphasizing the need for future clinical studies to assess the safety and efficacy of CAR-EVs in cancer patients. This review also summarizes preliminary findings and challenges, proposing strategies to improve EV targeting and cargo delivery. Additionally, this review highlights unexplored aspects of EV biology in the context of CAR T-cell therapies. In conclusion, CAR-EVs offer a viable option for cancer therapy, with potential advantages over conventional CAR T-cell therapies. However, future research is needed to optimize manufacturing, distribution, and clinical application for achieve maximum therapeutic efficacy and favorable patient outcomes.
    Keywords:  CAR-T cell therapy; CAR-T-cell-derived extracellular vesicles (CAR-EVs); cancer treatment; cell-free therapy
    DOI:  https://doi.org/10.1080/20415990.2025.2569298
  6. BMC Cancer. 2025 Oct 10. 25(1): 1553
      
    Keywords:  Exosomes; Hepatic stellate cells; Liver metastasis; MiR-125b-5p; PCBP1-AS1; Pancreatic cancer; TNFAIP3
    DOI:  https://doi.org/10.1186/s12885-025-14854-x
  7. Front Immunol. 2025 ;16 1642639
      Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy due to its intratumoral heterogeneity, aggressive progression, and resistance to multimodal treatment. Extracellular vesicles (EVs)-including exosomes and microvesicles-have gained attention as active contributors to these phenotypes by mediating intercellular signaling and molecular cargo transfer. HNSCC-derived EVs carry oncogenic and drug resistance proteins, along with microRNAs that promote immune evasion and EMT. Enrichment of microRNAs including miR-21, miR-214, and miR-221/222 within EVs supports angiogenesis, apoptosis evasion, and immune suppression. EV-associated PD-L1 impairs antigen presentation and T cell activity, contributing to resistance to checkpoint blockade. Additionally, EVs promote epithelial-to-mesenchymal transition and extracellular matrix remodeling, facilitating invasion and pre-metastatic niche formation. Through modulation of T cell function, macrophage polarization, and stromal recruitment, EVs help establish an immune-tolerant microenvironment. This review synthesizes current knowledge on the mechanistic roles of EVs in HNSCC and discusses their potential as diagnostic biomarkers and therapeutic targets.
    Keywords:  extracellular vesicles; head and neck squamous cell carcinoma; immune evasion; therapy resistance; tumor microenvironment
    DOI:  https://doi.org/10.3389/fimmu.2025.1642639